Trinity Biotech Plc Stock Performance
| TRIB Stock | USD 0.94 0.01 1.08% |
The entity has a beta of 1.19, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Trinity Biotech will likely underperform. At this point, Trinity Biotech plc has a negative expected return of -0.28%. Please make sure to validate Trinity Biotech's maximum drawdown, as well as the relationship between the accumulation distribution and day typical price , to decide if Trinity Biotech plc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Trinity Biotech plc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's forward indicators remain somewhat strong which may send shares a bit higher in January 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:5 | Dividend Date 2015-07-01 | Ex Dividend Date 2015-06-05 | Last Split Date 2024-02-23 |
1 | Parents began planning to take their kids out of NYC schools minutes after Zohran Mamdanis mayoral win | 11/05/2025 |
2 | Barings Supports the Continued Growth of Trinity Hunt Partners Portfolio Company, Acuvance | 11/12/2025 |
3 | Former Trinity Broadcasting headquarters is sold and set to be torn down for new housing | 11/21/2025 |
4 | Fans have just days to watch masterpiece and flawless thriller on Netflix | 12/02/2025 |
5 | Haley Carter on joining Washington Spirit, Michele Kangs vision and Trinity Rodmans future | 12/03/2025 |
6 | Players union says NWSL engaged in flagrant violation of Trinity Rodmans free agent rights | 12/04/2025 |
7 | Trinity Industries Valuation Check After Its Latest Dividend Increase and Ongoing Shareholder Payout Streak | 12/05/2025 |
8 | Former Georgia beauty queen Trinity Poague breaks down after being sentenced in murder of ex-boyfriends toddler son | 12/08/2025 |
9 | Trinity Consultants Acquires Meridian Consultants LLC | 12/09/2025 |
10 | Trinity Place Share Price Crosses Above 50-Day Moving Average Should You Sell | 12/10/2025 |
11 | Wood scores 21, Jacksonville takes down Trinity Baptist 122-49 | 12/12/2025 |
12 | Trinity Biotech Expands Global Rollout of High-Capacity Column System for FDA-Cleared HbA1c Testing Solution After Securing Regulatory Clearances | 12/15/2025 |
13 | Trinity Capital declares 0.51 dividend | 12/17/2025 |
| Begin Period Cash Flow | 3.7 M | |
| Total Cashflows From Investing Activities | -23 M |
Trinity Biotech Relative Risk vs. Return Landscape
If you would invest 120.00 in Trinity Biotech plc on September 20, 2025 and sell it today you would lose (26.00) from holding Trinity Biotech plc or give up 21.67% of portfolio value over 90 days. Trinity Biotech plc is currently does not generate positive expected returns and assumes 4.7582% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Trinity, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Trinity Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Trinity Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Trinity Biotech plc, and traders can use it to determine the average amount a Trinity Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0581
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TRIB |
Based on monthly moving average Trinity Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Trinity Biotech by adding Trinity Biotech to a well-diversified portfolio.
Trinity Biotech Fundamentals Growth
Trinity Stock prices reflect investors' perceptions of the future prospects and financial health of Trinity Biotech, and Trinity Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Trinity Stock performance.
| Return On Equity | -19.13 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.52) % | ||||
| Operating Margin | (0.43) % | ||||
| Current Valuation | 113.33 M | ||||
| Shares Outstanding | 18.63 M | ||||
| Price To Earning | 31.00 X | ||||
| Price To Book | 5.11 X | ||||
| Price To Sales | 0.29 X | ||||
| Revenue | 61.55 M | ||||
| Gross Profit | 21.44 M | ||||
| EBITDA | (16.91 M) | ||||
| Net Income | (31.79 M) | ||||
| Cash And Equivalents | 10.01 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 100.76 M | ||||
| Current Ratio | 3.66 X | ||||
| Book Value Per Share | (1.96) X | ||||
| Cash Flow From Operations | (4.19 M) | ||||
| Earnings Per Share | (1.80) X | ||||
| Market Capitalization | 15.89 M | ||||
| Total Asset | 103.29 M | ||||
| Retained Earnings | (79.12 M) | ||||
| Working Capital | 9.03 M | ||||
| Current Asset | 151 M | ||||
| Current Liabilities | 21 M | ||||
About Trinity Biotech Performance
By analyzing Trinity Biotech's fundamental ratios, stakeholders can gain valuable insights into Trinity Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Trinity Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Trinity Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 176.29 | 163.83 | |
| Return On Tangible Assets | (0.61) | (0.58) | |
| Return On Capital Employed | (0.30) | (0.28) | |
| Return On Assets | (0.31) | (0.29) | |
| Return On Equity | 0.90 | 0.95 |
Things to note about Trinity Biotech plc performance evaluation
Checking the ongoing alerts about Trinity Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Trinity Biotech plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Trinity Biotech plc generated a negative expected return over the last 90 days | |
| Trinity Biotech plc has some characteristics of a very speculative penny stock | |
| Trinity Biotech plc has high historical volatility and very poor performance | |
| Trinity Biotech plc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 61.55 M. Net Loss for the year was (31.79 M) with profit before overhead, payroll, taxes, and interest of 21.44 M. | |
| Trinity Biotech plc currently holds about 10.01 M in cash with (4.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. | |
| Trinity Biotech plc has a poor financial position based on the latest SEC disclosures | |
| Roughly 66.0% of the company shares are owned by institutional investors | |
| Latest headline from seekingalpha.com: Trinity Capital declares 0.51 dividend |
- Analyzing Trinity Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Trinity Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Trinity Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Trinity Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Trinity Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Trinity Biotech's stock. These opinions can provide insight into Trinity Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Trinity Stock analysis
When running Trinity Biotech's price analysis, check to measure Trinity Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trinity Biotech is operating at the current time. Most of Trinity Biotech's value examination focuses on studying past and present price action to predict the probability of Trinity Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trinity Biotech's price. Additionally, you may evaluate how the addition of Trinity Biotech to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |